Damn, I had a hunch they would issue more shares and dilute the current outstanding. Hate that!!!!!
Management would not be hurt by this because they get more shares to counter the dilution. Meanwhile, Ordinary shareholders like us get screwed.
GW is not making money hence they have to issue more shares to finance their clinical trials, payroll, pipelines...etc. Like I said, it comes down to FDA approval and getting your products out there to make profits. Or else you gonna just keep issuing more shares and shareholders take it in the chins.